January 19, 2021

The Globe and Mail | Rare Milestone Approaches for Canadian Biotech Sector as Aurinia Awaits FDA OK to Sell New Drug

Canadian-based biopharma, Aurinia Pharmaceuticals, is awaiting FDA approval of their promising treatment for lupus nephritis. With ambitious plans to take their drug to market on their own, Aurinia has raised a considerable amount of money and grown to over 300 employees.

For more from Sean Silcoff, with comments from our head of equity research, David Martin, click here.